Featured News

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

To guarantee the safety & comfort of our community, we have decided to take our 2020 CDF Turkey Trot virtual. Whether you’re 5 or 55, a marathoner or just starting your fitness journey, anyone can participate from anywhere!

Concern has been expressed in the celiac disease community that the FDA’s temporary food labeling requirements during COVID-19 apply to gluten. The FDA confirmed that the introduction of unlabeled gluten is not allowed in regulated food products.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

Each year, we proudly embrace the unity and generosity of our community during May Celiac Disease Awareness Month.

On Friday, I joined three of the leading celiac disease researchers in the world to present to the NIH’s Autoimmune Disease Coordinating Committee (ADCC) the findings from the CDF-sponsored First SSCD Consensus Workshop: Research Opportunities in Celiac Disease 2020.

We have been hearing from our community about COVID-19 and celiac disease and about our work at the Celiac Disease Foundation during the pandemic. We have answered the most frequently asked questions in a short video for you. 

People with celiac disease have a 10-fold greater risk for inflammatory bowel disease (IBD). Those with IBD have a 4-fold greater risk for celiac disease. A new study reviews the link between these two autoimmune disorders.

TAK-062, an orally administered synthetic enzyme that survives the acidity of the stomach and digests gluten effectively, has passed its phase 1 clinical drug trial, indicating it is safe to use in celiac patients.

A small pilot study suggests chemical pollutants might be an environmental factor associated with celiac disease in children. This is the first research to link the autoimmune disorder with persistent organic pollutants (POPs) detected in blood samples from celiac patients.